Intima Capital is a New York-based global alternative asset management firm that seeks to capture
superior, uncorrelated, risk-adjusted returns in healthcare and biotechnology.
The investment strategy is predicated on the understanding that biotechnology is an investible sector
that is fundamentally non-discretionary, uniquely inefficient, and disproportionately requires
specific scientific and clinical domain expertise.
The firm is focused on identifying long-term secular, economic, and scientific trends and then
establishing discrete long/short public equity, derivative, and opportunistic private equity
investments to best execute on these proprietary ideas.
3 Columbus Circle
New York, NY 10019